Associate Professor of Medicine, University S Fla College of Medicine
Oncology
Dr. Eduardo M. Sotomayor, MD
|
|
Give Review
Eduardo M. Sotomayor practices Oncology. He received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Eduardo M. Sotomayor is a published MD. He has 84 publications published. The most current publication "Tolerance and cancer: a critical issue in tumor immunology." Eduardo Sotomayor accepts Medicare payments and is registered with Medicare.gov.
Publications
- A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs.
- Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor Cell expansion and function.
- Biology and expression of CD30.
- Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting Cells.
- Primary B-Cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.
- Serum albumin retains independent prognostic significance in diffuse large B-Cell lymphoma in the post-rituximab era.
- Quantitative flow cytometric identification of aberrant T Cell clusters in erythrodermic cutaneous T Cell lymphoma. Implications for staging and prognosis.
- Quality of life outcomes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
- Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-Cell lymphoma survival and clonogenicity.
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in Cancer.
- Mantle Cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
- Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle Cell and other non-Hodgkin B-Cell lymphomas.
- Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and Cancer.
- EBV-positive diffuse large B-Cell lymphoma of the elderly: A case series from Peru.
- Human immunodeficiency virus (HIV)-negative plasmablastic Lymphoma: a single institutional experience and literature review.
- Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data.
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma.
- Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10.
- Epigenetic repolarization of T lymphocytes from chronic lymphocytic Leukemia patients using 5-aza-2'-deoxycytidine.
- Follicular dendritic Cell-dependent drug resistance of non-Hodgkin lymphoma involves Cell adhesion-mediated Bim down-regulation through induction of microRNA-181a.
- "Skulls and bones" new member: Th17.
- Mantle Cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.
- The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions.
- Treatment of chronic lymphocytic Leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and Immune tolerance.
- Immunosuppressive strategies that are mediated by tumor Cells.
- Monoclonal antibodies for B-Cell lymphomas: rituximab and beyond.
- In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-Cell activation by B-Cell lymphomas leading to antitumor immunity.
- Imatinib mesylate (STI-571) enhances antigen-presenting Cell function and overcomes tumor-induced CD4+ T-Cell tolerance.
- Arginase I production in the tumor microenvironment by mature myeloid Cells inhibits T-Cell receptor expression and antigen-specific T-Cell responses.
- Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-Cell anergy: dominant role of cross-tolerance to...
- A critical role for Stat3 signaling in Immune tolerance.
- Immunotherapy of hematologic malignancies: the road to the future.
- Cancer vaccines for hematologic malignancies.
- Advances in gene therapy for malignant Melanoma.
- Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-Cell lymph...
- Trisomy 9 in a patient with secondary Acute myelogenous leukemia detected by fluorescent in situ hybridization.
- Occurrence of both t(1;19) and t(8;14) in a patient with chronic lymphocytic Leukemia.
- Gene therapy for lung Cancer.
- Impaired activation of tumoricidal function in macrophages from mammary-tumor bearers - the role of IFN-gamma.
- Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.
- Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human ...
- PRDM1 is required for mantle Cell lymphoma response to bortezomib.
- Gene therapy for lung Cancer. An introduction.
- A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander Cell line (GM.CD40L) in the formulation of autologous tumor Cell-based vaccines for c...
- Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle Cell...
- Bone marrow stromal Cells prevent apoptosis of lymphoma Cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodg...
- Lymphoma Cell adhesion-induced expression of B Cell-activating factor of the TNF family in bone marrow stromal Cells protects non-Hodgkin''s B lymphoma Cells from apop...
- Modulation of the immune System by mammary tumor-derived factors.
- Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression.
- Cell adhesion induces p27Kip1-associated Cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-Cell and other non-Hodgkin B-Cell ...
- All-trans-retinoic acid eliminates immature myeloid Cells from tumor-bearing mice and improves the effect of vaccination.
- Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast Cancer.
- Expansion of myeloid suppressor Cells in SHIP-deficient mice represses allogeneic T Cell responses.
- CD40-independent pathways of T Cell help for priming of CD8(+) cytotoxic T lymphocytes.
- Induction of antigen-specific T Cell anergy: An early event in the course of tumor progression.
- Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor Cells.
- microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle Cell lymphoma.
- Follicular dendritic Cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin''s B-Cell lymphomas.
- Histone deacetylases and the immunological network: implications in Cancer and inflammation.
- Tolerance and Cancer: a critical issue in tumor immunology.
- Enhancement of macrophage tumouricidal activity by the alkaloid derivative Ukrain. In vitro and in vivo studies.
- Isolation of a nitric oxide inhibitor from mammary tumor Cells and its characterization as phosphatidyl serine.
- Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release.
- Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenoCarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived...
- In vivo blockade of CTLA-4 enhances the priming of responsive T Cells but fails to prevent the induction of tumor antigen-specific tolerance.
- A universal granulocyte-macrophage colony-stimulating factor-producing bystander Cell line for use in the formulation of autologous tumor Cell-based vaccines.
- Conversion of tumor-specific CD4+ T-Cell tolerance to T-Cell priming through in vivo ligation of CD40.
- Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting Cells is the dominant mechanism in the induction of T-Cell tolerance during B-Cell lymph...
- Mechanism of immune dysfunction in Cancer mediated by immature Gr-1+ myeloid cells.
- Sustaining the Graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
- Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult Acute lymphoblastic leukemia: impact of induction Ara-C dos...
- Non-Hodgkin''s Lymphoma. Clinical practice guidelines in oncology.
- Cellular and molecular mechanisms of tumor-induced T-Cell tolerance.
- Identification of a novel negative role of flagellin in regulating IL-10 production.
- Immune tolerance in breast Cancer.
- Non-Hodgkin''s Lymphomas.
- TLR5 ligation by flagellin converts tolerogenic dendritic Cells into activating antigen-presenting Cells that preferentially induce T-helper 1 responses.
- Enhanced CD8 T Cell cross-presentation by macrophages with targeted disruption of STAT3.
- Circumventing Immune tolerance through epigenetic modification.
- Restoring the functional immunogenicity of chronic lymphocytic Leukemia using epigenetic modifiers.
- A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous Leukemia treated with tyrosine kinase inhibitors.
- Epstein-Barr virus-positive diffuse large B-Cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of ...
Schools
Universidad Nacional Federico Villarreal Facultad De Medicina Humana 39hipolito Unanue39
Jackson Memorial Hospital
Johns Hopkins University
University Of Miami
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- AvMed
- Blue Card PPO
- Blue Care HMO
- BlueDental Choice
- NetworkBlue
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Employer Group Open Access HMO
- Employer Group PPO
- Federal Employee Program (FEP)
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Choice Care PPO
- Preferred PPO
- Select HMO
- Tampa Bay CoreNet
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- POMCO Group
- Choice Plus POS
- Neighborhood Health Partnership
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Johns Hopkins University -
Jackson Memorial Hospital - Jackson Health System -
National University of Federico Villarreal Faculty of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1912912536 | |
| NPPES Provider LastName | SOTOMAYOR | |
| NPPES Provider FirstName | EDUARDO | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 98.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912912536 |
| Last Name Of The Provider | SOTOMAYOR |
| First Name Of The Provider | EDUARDO |
| View All |
Similar Doctors
|
Dr. Amber L. Flaherty, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael V. Jaglal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joyson J. Karakunnel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey M. Greenberg, MD |
|
Dr. Geoffrey T. Gibney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kendra L. Sweet, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Scott J. Antonia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen G. Patterson, MD |
|
|
Dr. Mohamad A. Hussein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jingsong Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Daniel Sullivan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Y K Peter Park, MD |
|
|
Dr. Ramesh Shah, MD
This Doctor is OpenDoctor Recommended.
|